Shots:

• The approval is based on P-III IMpower010 study Tecentriq vs BSC in 1005 patients in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
• The results showed a 34% reduction in risk of disease recurrence or death in people with Stage II-IIIA NSCLC whose tumors express PD-L1≥1%- safety data were consistent with known safety profile & no new safety signals were observed
• The FDA has reviewed & approved the supplemental application under the RTOR program for safe & effective treatments to patients imminently. The company has an extensive program for Tecentriq including ongoing & planned P-III studies for multiple cancers

  | Ref: Businesswire | Image: Xconomy